In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
ESMO 2025 Review: Bring me the horizon
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...